RxDoctor Payments Data

Abraham Knoll, MD

Urology · Wayne, NJNPI 1932143633

Payments from drug & device makers

$1,876in general payments, 2019–2025

Across 104 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$651
  • 180 Medical, Inc.$151
  • Tolmar, Inc.$140
  • Tolmar Pharmaceuticals, Inc.$101
  • Sumitomo Pharma America, Inc.$97
  • Astellas Pharma US Inc$68
  • plus $669 from 25 others

What the payments were for

  • Food & beverage$1,86299%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,876 in reported general payments places this provider in the 40th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$214,282
Medicare patients
554
Services billed
4,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron59$58,300
GemtesaVibegron35$35,810
Potassium Citrate ErPotassium Citrate71$15,014
Tamsulosin Hcl540$10,768
Silodosin52$5,509
Testosterone28$4,795
Dutasteride104$4,555
Finasteride204$3,190
Methenamine Hippurate21$2,614
Oxybutynin Chloride ErOxybutynin Chloride70$2,098
Dexlansoprazole DrDexlansoprazole12$1,923
Potassium Citrate-Citric AcidPotassium Citrate/Citric Acid11$1,717
Solifenacin Succinate18$1,133
Alfuzosin Hcl ErAlfuzosin Hcl26$810
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst33$563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$68$58,30059 claims
Sumitomo Pharma America, Inc.Gemtesa$97$35,81035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 401 urology providers in New Jersey.

Other urology in Wayne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →